Skip to Content
Investing Specialists

Weekly Wrap: The Best 529 Plans and Scariest Stock Picks

We recap the week on and note the most popular stocks, funds, and exchange-traded funds.

Editor's note: Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.

Editor's Picks
The Top 529 College Savings Plans of 2020
A look at how 529 investments stack up under our enhanced methodology.

3 Funds for an Evolving Market
Is the market overvaluing growth, undervaluing innovation, or getting things right?

Why We've Downgraded This Fine Vanguard Fund
Vanguard Health Care manager Jean Hynes is taking on a much larger role at subadvisor Wellington.

What Is the Neutral Portfolio?
Balanced funds are the standard, but with little justification.

10 Scary Stocks: 2020 Edition
These are the most overpriced stocks in our coverage universe today.

Sustainability Matters: U.S. Investors Continue to Endorse Sustainable Investing
Last year's record for flows was broken in July.

Portfolio Planning and Personal Finance With Christine Benz
A Checklist for Open Enrollment Season
If you're signing up for employer-provided benefits, don't just re-up for last year's choices; read this first.

Guess What? It May Actually Be Different This Time
In volatile market environments, tune out the pundits and take a look in the mirror.

Mutual Funds and Exchange-Traded Funds
What's Behind the Strong Performance of Big Funds?
Low fees give the largest active funds a big boost.

How Objective Is Your Index Fund?
Benchmark construction is not as mechanical as you might think.

T. Rowe Price's Jerome Clark on Target-Date Funds
Hear from our 2020 Outstanding Portfolio Manager Award winner.

This Bond Fund Provides Broad Diversification at a Low Cost
Silver-rated Vanguard Total Corporate Bond ETF is a compelling option.

Tesla's Moat Rating Gets a Boost
We expect the EV maker to keep innovating to stay ahead of competitors.

3 Competitive Stocks to Consider
These newly rated stocks all earn Morningstar Economic Moat Ratings of narrow or wide.

Coronavirus Surges, Stocks Sink
A surge in new coronavirus cases has sent stocks on a downward spiral.

Trick or Treat? 3 Chocolate Stocks to Watch
Long-term investors may want to look at these stocks, which have strong fundamentals, product innovation, and bountiful demand from emerging markets.

Are Alternative-Weighted Indexes Safer Than the S&P?
Their exposure to smaller, value-oriented stocks brings different risks.

More Dividends Come Out of Shell
The supermajor has introduced a new framework for shareholder returns.

Should You Add These Household Brands to Your Portfolio?
Here's our take on Clorox, Colgate-Palmolive, and Procter & Gamble.

What's Next for Rolls-Royce?
Rolls-Royce has had a difficult time in recent years and recently announced a capital-raising. Morningstar analyst Joachim Kotze looks at the prospects for the business.

Stock Analyst Updates
Dunkin' Buyout by Inspire Brands Would Be Excellent
The reported buyout price is a 42% premium to our $75 fair value estimate.

Bayer's Announced Acquisition Adds Needed Boost
The wide-moat drug manufacture plans to acquire Asklepios BioPharmaceuticals.

Merck Posts Strong Third Quarter
We continue to view Merck as undervalued, with the market not fully appreciating the firm's strong immuno-oncology platform.

Pfizer Faces Modest Pressures in Q3
The wide-moat drug manufacturer plans to release key data on COVID-19 vaccine shortly.

Microsoft Reports Material Upside; Raise FVE to $235
A variety of generally minor model refinements drive our Microsoft fair value estimate to $235 from $228 per share. We still see more than 10% upside to this high-quality wide-moat name.

Strong Flows and Market Gains Lift T. Rowe Price
We're likely to raise our fair value estimate for the asset manager.

Ford Rebounds From Pandemic With Strong Q3, Q4 Won't Be
Ford had a strong third quarter with adjusted diluted EPS of $0.65 up 91% year over year and far ahead of the $0.19 Refinitiv consensus. We are raising our fair value estimate to $13 from $8.

Lowering Our Gilead FVE to $75 After Q3
We have once again lowered our fair value estimate for Gilead, and now value the firm at $75 per share following third-quarter earnings.

Rekenthaler Report
A Stock Market Bubble Is Forming
However, it has not (yet) become a mania.

Advisor Insights
A Unique Solution for Concentrated Stock Positions
The ins and outs of exchange funds.

The Long View Podcast
Peter Hayes: Surveying the Municipal-Bond Landscape
BlackRock's head of muni-bond investing on how states and municipalities are faring, where stimulus is most needed, and the risks and opportunities that investors face.

Not All Momentum Rallies are Led by Tech; This One Sure Is
Investors often equate momentum markets with growth and tech stocks--and this year's rally met those qualifications. But that's not always the case.

Most Requested Stock Quotes

Most Requested Fund Quotes
Vanguard 500 Index
Vanguard Dividend Growth
T. Rowe Price Blue Chip Growth
Fidelity 500 Index
Vanguard Total Stock Market Index

Most Requested ETF Quotes 
ARK Innovation ETF
Invesco QQQ Trust
Vanguard S&P 500 ETF
Vanguard High Dividend Yield ETF

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.